Cytek Biosciences (CTKB) EBIT (2020 - 2026)

Cytek Biosciences has reported EBIT for 7 years, with the latest figure at -$18.5 million in Q1 2026.

• For the quarter ending Q1 2026, EBIT fell 23.29% year-over-year to -$18.5 million; the trailing twelve-month figure through Mar 2026 stood at -$43.9 million (down 77.16% YoY), and the FY2025 full-year result was -$40.4 million, down 96.77% from the prior year.
• EBIT for Q1 2026 stood at -$18.5 million, down from -$5.6 million in the prior quarter.
• The five-year high for EBIT was $3.0 million in Q4 2024, with the low at -$18.5 million in Q1 2026.
• Historically, EBIT has averaged -$6.4 million across 5 years, with a median of -$6.4 million in 2023.
• Annual changes were most pronounced in 2023 — EBIT sank 924.35% — and 2024, when it surged 2279.56%.
• Cytek Biosciences' EBIT stood at $84000.0 in 2022, then tumbled by 263.1% to -$137000.0 in 2023, then surged by 2279.56% to $3.0 million in 2024, then slumped by 287.34% to -$5.6 million in 2025, then tumbled by 230.05% to -$18.5 million in 2026.
• The last three EBIT figures came in at -$18.5 million (Q1 2026), -$5.6 million (Q4 2025), and -$9.2 million (Q3 2025), per Business Quant data.